On March 27, 2026, Akebia Therapeutics announced the resignation of Dr. Steven C. Gilman from the Board, effective April 1, 2026, and the election of Dr. Philip J. Vickers as a new director, who will receive an annual cash retainer of $50,000 and options for 214,400 shares at an exercise price of $1.41.